Data are taken from references 7 and 8 and the present study as in Figure 4 . All calculations refer to 28 day assessments, and therefore do not take into account first recurrences after this time point. The estimates are approximate as numbers are relatively small and so confidence intervals for the proportions in each study are wide.
If the recurrence rate following treatment = R%, recrudescence rate = S%, and relapse = T%, then
Assuming artesunate is completely curative for blood stage infection 8 (but has no hypnozoitocidal activity) then R art = T
(2) Thus any differences in recurrence rates between primaquine dosage regimens in artesunate-primaquine combination treatments result from differences in relapse rates ( Figure 4 open circles).
Comparing recurrence rates with and without concomitant artesunate. For artesunate + 7 days primaquine 30 (total dose 210 mg) R art = T = 12%
For 7 days primaquine 30 (total dose 210 mg) without artesunate R 30 = 29%, and as T 30 = 12%, and as from (1) In other words the difference in recrudescence rates between primaquine 30 mg/day for 7 days and 60 mg/day for 7 days without artesunate (S 60 − S 30 ) is 17 − 3 = 14% If this is correct then the 22% difference (R 30 − R 60 = 29% − 7 % = 22%) without artesunate comprises approximately a 14% difference in recrudescence rates plus an 8% difference in relapse rates. This compares with an 8% difference between the 2 regimens with artesunate 7 attributable only to a difference in relapse rates.
Dose-response relationships. If maximum relapse prevention (i.e., T = 0) corresponds to prevention of 50% of recurrences 8 then a) 7 days primaquine 60 provides (50 − 4/50) = 92% of the maximal hypnozoitocidal effect and b) 7 days primaquine 30 provides (50 − 12/50) = 72% of the maximal hypnozoitocidal effect.
Assuming all infections could recrudesce, and censoring for those infections which relapse within 28 days, then a) 7 days primaquine 60 alone provides (100 − 4) −3/(100 − 4) = 97% of maximal blood stage curative activity. b) 7 days primaquine 30 alone provides (100 − 12) −17 /(100 − 12) = 81 % of maximal blood stage curative activity.
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